

BOB ICB and Frimley ICB Priorities Committee Clinical Commissioning Policy Statement

Policy Number/ Name	BOBFPC5 Anti-VEGF Treatments and Dexamethasone Implants for Macular Oedema caused by Central and Branch Retinal Vein Occlusion
Date of BOB ICB Adoption	January 2024

Retinal vein occlusion (RVO) is a common cause of reduced vision due to retinal vascular disease.

The Buckinghamshire, Oxfordshire, and Berkshire West ICB and Frimley ICB Priorities Committee has considered the relevant NICE Technology Appraisals^{1,2,3,4} and recent evidence for the use of anti-VEGF intravitreal injections and dexamethasone implants for macular oedema caused by central and branch RVO. The use of any of these treatments is recommended in line with the associated NICE technology appraisal; the requirement to use laser therapy before these treatments as stated in NICE technology appraisal guidance for the treatment of branch RVO need not apply.

NHS England⁵ recommends that clinicians consider ranibizumab biosimilar where the Technology Appraisal criteria are met, it is clinically appropriate, and there is capacity to do so.

Note this policy should be read in conjunction with TVPC45: Sequential use of biologic therapy in Ophthalmology, which in addition to sequential use, also provides recommendations on stopping criteria.

NOTES:

- Potentially exceptional circumstances may be considered by a patient's ICB where there is evidence of significant health status impairment (e.g. inability to perform activities of daily living) and there is evidence that the intervention sought would improve the individual's health status.
- This policy was developed and recommended by Thames Valley Priorities Committee which was the predecessor of Buckinghamshire, Oxfordshire, and Berkshire West ICB and Frimley ICB Priorities Committee. Amendments have been approved by BOB APC.
- This policy will be reviewed in the light of new evidence or new national guidance, e.g. from NICE.
- BOBFPC clinical policies can be viewed at [Clinical Commissioning Policy Statements & IFRs | BOB ICB](#)

Version	Date	Reason for change
Version 1	April 2014	
Version 2	January 2019	Updated to reflect additional TA guidance
Version 3	July 2022	Updated to include national recommendations on biosimilars. Amendments approved by BOB APC (changes not reviewed by BOBFPC)

¹ <https://www.nice.org.uk/guidance/ta305>

² <https://www.nice.org.uk/guidance/ta409>

³ <https://www.nice.org.uk/guidance/ta229>

⁴ <https://www.nice.org.uk/guidance/ta283>

⁵ <https://www.england.nhs.uk/wp-content/uploads/2022/08/B1720-Commissioning-recommendations-following-national-procurement-medical-retinal-vascular-medicines-August-2.pdf>